Evaluation of safety in biomarker driven multiple agent phase IB trial

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Tyner and colleagues in the Center for Hematological Malignancies, Knight Cancer Institute, at the Oregon Health & Science University have recently developed a novel kinase-inhibitor assay and rapid mutation screening to identify molecularly targeted drugs to which patient leukemic cells are sensitive. As a proof of concept and feasibility trial, they proposed a phase IB trial focusing on feasibility and safety of an assay-based kinase-inhibitor treatment assignment in combination with the standard induction chemotherapy among newly diagnosed acute myeloid leukemia patients. Because each patient receives one of five kinase inhibitors in combination with standard chemotherapy, the sample size for each kinase inhibitor group is varied and limited. In addition, there is a different toxicity profile associated with each inhibitor, making safety assessment challenging. We will discuss a continuous toxicity monitoring plan in biomarker driven, multiple agent feasibility and safety trials, and evaluate its operating characteristics in a simulation study.

Original languageEnglish (US)
Title of host publicationFrontiers of Biostatistical Methods and Applications in Clinical Oncology
PublisherSpringer Singapore
Pages53-64
Number of pages12
ISBN (Electronic)9789811001260
ISBN (Print)9789811001246
DOIs
StatePublished - Oct 3 2017

Fingerprint

Biomarkers
Inhibitor
Phosphotransferases
Safety
Evaluation
evaluation
Chemotherapy
Toxicity
induction
Induction Chemotherapy
cancer
Hematologic Neoplasms
Safety Assessment
Acute Myeloid Leukemia
Sample Size
monitoring
Operating Characteristics
drug
Leukemia
simulation

Keywords

  • Continuous toxicity monitoring
  • Early phase clinical trials
  • Multi-drug trials
  • Phase I oncology trials
  • Precision medicine
  • Safety evaluation

ASJC Scopus subject areas

  • Medicine(all)
  • Mathematics(all)
  • Social Sciences(all)

Cite this

Mori, M. T., Daffé, R., Park, B., & Tyner, J. (2017). Evaluation of safety in biomarker driven multiple agent phase IB trial. In Frontiers of Biostatistical Methods and Applications in Clinical Oncology (pp. 53-64). Springer Singapore. https://doi.org/10.1007/978-981-10-0126-0_5

Evaluation of safety in biomarker driven multiple agent phase IB trial. / Mori, Motomi (Tomi); Daffé, Racky; Park, Byung; Tyner, Jeffrey.

Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, 2017. p. 53-64.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mori, MT, Daffé, R, Park, B & Tyner, J 2017, Evaluation of safety in biomarker driven multiple agent phase IB trial. in Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, pp. 53-64. https://doi.org/10.1007/978-981-10-0126-0_5
Mori MT, Daffé R, Park B, Tyner J. Evaluation of safety in biomarker driven multiple agent phase IB trial. In Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore. 2017. p. 53-64 https://doi.org/10.1007/978-981-10-0126-0_5
Mori, Motomi (Tomi) ; Daffé, Racky ; Park, Byung ; Tyner, Jeffrey. / Evaluation of safety in biomarker driven multiple agent phase IB trial. Frontiers of Biostatistical Methods and Applications in Clinical Oncology. Springer Singapore, 2017. pp. 53-64
@inbook{803b87e9ccf84f138437eb2ee54da26a,
title = "Evaluation of safety in biomarker driven multiple agent phase IB trial",
abstract = "Tyner and colleagues in the Center for Hematological Malignancies, Knight Cancer Institute, at the Oregon Health & Science University have recently developed a novel kinase-inhibitor assay and rapid mutation screening to identify molecularly targeted drugs to which patient leukemic cells are sensitive. As a proof of concept and feasibility trial, they proposed a phase IB trial focusing on feasibility and safety of an assay-based kinase-inhibitor treatment assignment in combination with the standard induction chemotherapy among newly diagnosed acute myeloid leukemia patients. Because each patient receives one of five kinase inhibitors in combination with standard chemotherapy, the sample size for each kinase inhibitor group is varied and limited. In addition, there is a different toxicity profile associated with each inhibitor, making safety assessment challenging. We will discuss a continuous toxicity monitoring plan in biomarker driven, multiple agent feasibility and safety trials, and evaluate its operating characteristics in a simulation study.",
keywords = "Continuous toxicity monitoring, Early phase clinical trials, Multi-drug trials, Phase I oncology trials, Precision medicine, Safety evaluation",
author = "Mori, {Motomi (Tomi)} and Racky Daff{\'e} and Byung Park and Jeffrey Tyner",
year = "2017",
month = "10",
day = "3",
doi = "10.1007/978-981-10-0126-0_5",
language = "English (US)",
isbn = "9789811001246",
pages = "53--64",
booktitle = "Frontiers of Biostatistical Methods and Applications in Clinical Oncology",
publisher = "Springer Singapore",

}

TY - CHAP

T1 - Evaluation of safety in biomarker driven multiple agent phase IB trial

AU - Mori, Motomi (Tomi)

AU - Daffé, Racky

AU - Park, Byung

AU - Tyner, Jeffrey

PY - 2017/10/3

Y1 - 2017/10/3

N2 - Tyner and colleagues in the Center for Hematological Malignancies, Knight Cancer Institute, at the Oregon Health & Science University have recently developed a novel kinase-inhibitor assay and rapid mutation screening to identify molecularly targeted drugs to which patient leukemic cells are sensitive. As a proof of concept and feasibility trial, they proposed a phase IB trial focusing on feasibility and safety of an assay-based kinase-inhibitor treatment assignment in combination with the standard induction chemotherapy among newly diagnosed acute myeloid leukemia patients. Because each patient receives one of five kinase inhibitors in combination with standard chemotherapy, the sample size for each kinase inhibitor group is varied and limited. In addition, there is a different toxicity profile associated with each inhibitor, making safety assessment challenging. We will discuss a continuous toxicity monitoring plan in biomarker driven, multiple agent feasibility and safety trials, and evaluate its operating characteristics in a simulation study.

AB - Tyner and colleagues in the Center for Hematological Malignancies, Knight Cancer Institute, at the Oregon Health & Science University have recently developed a novel kinase-inhibitor assay and rapid mutation screening to identify molecularly targeted drugs to which patient leukemic cells are sensitive. As a proof of concept and feasibility trial, they proposed a phase IB trial focusing on feasibility and safety of an assay-based kinase-inhibitor treatment assignment in combination with the standard induction chemotherapy among newly diagnosed acute myeloid leukemia patients. Because each patient receives one of five kinase inhibitors in combination with standard chemotherapy, the sample size for each kinase inhibitor group is varied and limited. In addition, there is a different toxicity profile associated with each inhibitor, making safety assessment challenging. We will discuss a continuous toxicity monitoring plan in biomarker driven, multiple agent feasibility and safety trials, and evaluate its operating characteristics in a simulation study.

KW - Continuous toxicity monitoring

KW - Early phase clinical trials

KW - Multi-drug trials

KW - Phase I oncology trials

KW - Precision medicine

KW - Safety evaluation

UR - http://www.scopus.com/inward/record.url?scp=85042654888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042654888&partnerID=8YFLogxK

U2 - 10.1007/978-981-10-0126-0_5

DO - 10.1007/978-981-10-0126-0_5

M3 - Chapter

AN - SCOPUS:85042654888

SN - 9789811001246

SP - 53

EP - 64

BT - Frontiers of Biostatistical Methods and Applications in Clinical Oncology

PB - Springer Singapore

ER -